Latest Headlines

1. Sygnature Discovery Unveils Strategic Rebrand To Cement Status As A Global Drug Discovery Partner 2/19/2026

   Sygnature Discovery, a leading drug discovery contract research organisation (CRO), has today announced a strategic brand relaunch, including a new website, cementing its position as a global drug discovery partner.

2. Merck And Mayo Clinic Announce New Research And Development Collaboration To Support AI-Enabled Drug Discovery And Precision Medicine 2/18/2026

   Merck, known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development.

3. Insilico Medicine Initiates AI-Driven Collaboration With Leading Global Cancer Center To Identify Novel Targets For Gastroesophageal Cancers 2/17/2026

   Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies.

4. TuHURA Files Investigational New Drug Application For TBS-2025 In The Treatment Of Blood-Related Cancers 2/17/2026

   TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration's (FDA) Division of Hematologic Malignancies 1 (DHM1) for the study of TBS-2025, a novel VISTA inhibiting antibody, for the treatment of mutNPM1 relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) in combination with a menin inhibitor.

5. U.S. Food And Drug Administration Accepts Bristol Myers Squibb's New Drug Application For Iberdomide In Patients With Relapsed Or Refractory Multiple Myeloma 2/17/2026

   Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab + dexamethasone - IberDd) in patients with relapsed or refractory multiple myeloma (RRMM).

6. Harmony Biosciences Receives U.S. Food And Drug Administration Approval For WAKIX (pitolisant) For The Treatment Of Cataplexy In Pediatric Narcolepsy 2/17/2026

   Harmony Biosciences today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy.

7. BostonGene Announces Strategic Collaboration With Daiichi Sankyo To Accelerate Drug Development Through AI-Driven Multimodal Analytics 2/17/2026

   BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo.

8. Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance For Filing Of New Drug Application For Tirabrutinib In Patients With Relapsed Or Refractory PCNSL 2/17/2026

   Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible, second generation Bruton tyrosine kinase inhibitor, for the treatment of relapsed or refractory primary central nervous system lymphoma (R/R PCNSL).

9. Twist Bioscience Expands Antibody Discovery Offering With Bispecific Licensing Agreement 2/17/2026

   Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement withInvenra Inc.

10. Nuclera And Leadxpro Partner To Accelerate Structure-Based Drug Design For Complex Membrane Proteins 2/17/2026

    Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership.